(BCRX) BioCryst Pharmaceuticals - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 2.375m USD | Total Return: 46.1% in 12m

Influenza Treatments, Rare Disease Therapies, Immune Disorders
Total Rating 69
Safety 31
Buy Signal 1.00
Drug Manufacturers - Specialty & Generic
Industry Rotation: +2.2
Market Cap: 2.38B
Avg Turnover: 54.6M USD
ATR: 5.01%
Peers RS (IBD): 45.8
Risk 5d forecast
Volatility53.9%
Rel. Tail Risk-17.8%
Reward TTM
Sharpe Ratio1.00
Alpha15.74
Character TTM
Beta0.800
Beta Downside1.041
Drawdowns 3y
Max DD53.12%
CAGR/Max DD0.11
EPS (Earnings per Share) EPS (Earnings per Share) of BCRX over the last years for every Quarter: "2021-03": -0.36, "2021-06": -0.24, "2021-09": -0.33, "2021-12": -0.1, "2022-03": -0.4, "2022-06": -0.32, "2022-09": -0.23, "2022-12": -0.38, "2023-03": -0.28, "2023-06": -0.24, "2023-09": -0.19, "2023-12": -0.28, "2024-03": -0.17, "2024-06": -0.06, "2024-09": -0.07, "2024-12": -0.13, "2025-03": 0.0001, "2025-06": 0.02, "2025-09": 0.16, "2025-12": 1.1212,
EPS CAGR: 214.47%
EPS Trend: 76.2%
Last SUE: 4.00
Qual. Beats: 2
Revenue Revenue of BCRX over the last years for every Quarter: 2021-03: 19.059, 2021-06: 49.959, 2021-09: 40.994, 2021-12: 47.158, 2022-03: 49.923, 2022-06: 65.532, 2022-09: 75.827, 2022-12: 79.545, 2023-03: 68.778, 2023-06: 82.491, 2023-09: 86.742, 2023-12: 93.401, 2024-03: 92.761, 2024-06: 109.332, 2024-09: 117.085, 2024-12: 131.534, 2025-03: 145.534, 2025-06: 163.353, 2025-09: 159.395, 2025-12: 406.555,
Rev. CAGR: 74.94%
Rev. Trend: 92.9%
Last SUE: 4.00
Qual. Beats: 1

Warnings

Altman Z'' -4.75 < 1.0 - financial distress zone

Tailwinds

Supp Ema20 Pead

Description: BCRX BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. (BCRX) is a biotechnology company focused on developing therapies for rare diseases. The companys business model centers on the research, development, and commercialization of both small-molecule and protein therapeutics.

BCRX currently markets peramivir injection for influenza and ORLADEYO for hereditary angioedema. The pharmaceutical sector often involves lengthy and costly drug development pipelines. Its pipeline includes BCX17725 for Netherton syndrome (Phase 1), Avoralstat for diabetic macular edema (preclinical), and BCX10013 for complement-mediated diseases, along with other oral inhibitors.

The company maintains various collaborations and in-license agreements with pharmaceutical companies, government agencies, and academic institutions, which are common in the biotechnology industry to share development costs and expertise. For a deeper understanding of BCRXs financial health and market position, further research on platforms like ValueRay is recommended.

Headlines to Watch Out For
  • ORLADEYO sales growth drives revenue expansion
  • Pipeline development success impacts future valuation
  • Regulatory approvals for new drugs create upside
  • Competition in rare disease market limits growth
Piotroski VR‑10 (Strict) 7.0
Net Income: 263.9m TTM > 0 and > 6% of Revenue
FCF/TA: 0.64 > 0.02 and ΔFCF/TA 74.72 > 1.0
NWC/Revenue: 23.81% < 20% (prev 58.04%; Δ -34.23% < -1%)
CFO/TA 0.64 > 3% & CFO 330.9m > Net Income 263.9m
Net Debt (387.6m) to EBITDA (351.3m): 1.10 < 3
Current Ratio: 2.06 > 1.5 & < 3
Outstanding Shares: last quarter (219.3m) vs 12m ago 5.73% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 174.2% > 50% (prev 91.90%; Δ 82.27% > 0%)
Interest Coverage Ratio: 4.39 > 6 (EBITDA TTM 351.3m / Interest Expense TTM 78.9m)
Altman Z'' -4.75
A: 0.41 (Total Current Assets 404.3m - Total Current Liabilities 196.1m) / Total Assets 514.2m
B: -2.93 (Retained Earnings -1.51b / Total Assets 514.2m)
C: 0.69 (EBIT TTM 346.3m / Avg Total Assets 502.3m)
D: -2.37 (Book Value of Equity -1.50b / Total Liabilities 633.3m)
Altman-Z'' Score: -4.75 = D
Beneish M -2.28
DSRI: 0.70 (Receivables 106.8m/79.1m, Revenue 874.8m/450.7m)
GMI: 1.00 (GM 97.74% / 97.27%)
AQI: 1.78 (AQ_t 0.18 / AQ_t-1 0.10)
SGI: 1.94 (Revenue 874.8m / 450.7m)
TATA: -0.13 (NI 263.9m - CFO 330.9m) / TA 514.2m)
Beneish M-Score: -2.28 (Cap -4..+1) = BBB
What is the price of BCRX shares? As of April 10, 2026, the stock is trading at USD 9.89 with a total of 4,445,302 shares traded.
Over the past week, the price has changed by +9.65%, over one month by +14.73%, over three months by +33.65% and over the past year by +46.09%.
Is BCRX a buy, sell or hold? BioCryst Pharmaceuticals has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy BCRX.
  • StrongBuy: 6
  • Buy: 5
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the BCRX price?
Analysts Target Price 21.3 115.4%
BioCryst Pharmaceuticals (BCRX) - Fundamental Data Overview as of 08 April 2026
P/E Trailing = 7.8264
P/E Forward = 112.3596
P/S = 2.7149
P/B = 56.5858
P/EG = 9.3878
Revenue TTM = 874.8m USD
EBIT TTM = 346.3m USD
EBITDA TTM = 351.3m USD
Long Term Debt = 427.2m USD (from longTermDebt, last quarter)
Short Term Debt = 40.1m USD (from shortTermDebt, last quarter)
Debt = 477.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 387.6m USD (from netDebt column, last quarter)
Enterprise Value = 2.58b USD (2.38b + Debt 477.3m - CCE 274.7m)
Interest Coverage Ratio = 4.39 (Ebit TTM 346.3m / Interest Expense TTM 78.9m)
EV/FCF = 7.85x (Enterprise Value 2.58b / FCF TTM 328.5m)
FCF Yield = 12.74% (FCF TTM 328.5m / Enterprise Value 2.58b)
FCF Margin = 37.55% (FCF TTM 328.5m / Revenue TTM 874.8m)
Net Margin = 30.16% (Net Income TTM 263.9m / Revenue TTM 874.8m)
 Gross Margin = unknown ((Revenue TTM 874.8m - Cost of Revenue TTM 19.8m) / Revenue TTM)
 Tobins Q-Ratio = 5.01 (Enterprise Value 2.58b / Total Assets 514.2m)
Interest Expense / Debt = 2.96% (Interest Expense 14.1m / Debt 477.3m)
Taxrate = 0.88% (2.17m / 248.0m)
NOPAT = 343.2m (EBIT 346.3m * (1 - 0.88%))
Current Ratio = 2.06 (Total Current Assets 404.3m / Total Current Liabilities 196.1m)
 Debt / Equity = -4.01 (negative equity) (Debt 477.3m / totalStockholderEquity, last quarter -119.2m)
 Debt / EBITDA = 1.10 (Net Debt 387.6m / EBITDA 351.3m)
Debt / FCF = 1.18 (Net Debt 387.6m / FCF TTM 328.5m)
Total Stockholder Equity = -345.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 52.53% (Net Income 263.9m / Total Assets 514.2m)
 RoE = -76.45% (negative equity) (Net Income TTM 263.9m / Total Stockholder Equity -345.1m)
 RoCE = 421.8% (EBIT 346.3m / Capital Employed (Equity -345.1m + L.T.Debt 427.2m))
RoIC = 119.1% (NOPAT 343.2m / Invested Capital 288.2m)
WACC = 7.82% (E(2.38b)/V(2.85b) * Re(8.80%) + D(477.3m)/V(2.85b) * Rd(2.96%) * (1-Tc(0.01)))
Discount Rate = 8.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.34%
[DCF] Terminal Value 71.54% ; FCFF base≈328.5m ; Y1≈215.7m ; Y5≈98.6m
[DCF] Fair Price = 6.52 (EV 2.02b - Net Debt 387.6m = Equity 1.63b / Shares 250.8m; r=7.82% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 76.23 | EPS CAGR: 214.5% | SUE: 4.0 | # QB: 2
Revenue Correlation: 92.94 | Revenue CAGR: 74.94% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.13 | Chg7d=+0.000 | Chg30d=-0.017 | Revisions Net=+1 | Analysts=3
EPS current Year (2026-12-31): EPS=0.48 | Chg7d=+0.000 | Chg30d=+0.048 | Revisions Net=+1 | Growth EPS=-24.7% | Growth Revenue=-25.6%
EPS next Year (2027-12-31): EPS=0.80 | Chg7d=+0.000 | Chg30d=+0.059 | Revisions Net=+1 | Growth EPS=+67.8% | Growth Revenue=+12.6%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -4.0% (Discount Rate 8.8% - Earnings Yield 12.8%)
[Growth] Growth Spread = +4.1% (Analyst 0.1% - Implied -4.0%)
External Resources
Dataroma Stockcircle